Cell Cycle

Cell cycle is the entire process of cell division from the completion of one division to the end of the next division and is divided into two phases: interphase and division. Life is a continuous process passed from generation to generation and is therefore a process of constant renewal and starting from scratch. Thus, it is a process of constant renewal and starting from scratch. The life of a cell begins with the division of its parent cell and ends with the formation of its daughter cells, or the death of the cell itself. Usually, the formation of daughter cells is considered to mark the end of cell division. The cell cycle is the process from the formation of daughter cells at one cell division to the formation of daughter cells at the next cell division. During this process, the genetic material of the cell is copied and distributed equally to the two daughter cells.

Cat. No.	Product name
BP13389	NSC632839
BP13389	NSC632839 is a nonselective isopeptidase inhibitor, which inhibits USP2 (EC50: 45±4 μM), USP7 (EC50: 37±1 μM), and SENP2 (EC50: 9.8±1.8 μM).
BP13390	NU2058
BP13390	NU2058 is a guanine-based CDK inhibitor, also inhibits DNA topoisomerase II ATPase activity.
BP13391	NU6027
BP13391	NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.
BP13392	NU6140
BP13392	NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM). It shows 10- to 36-fold selectivity over other CDKs. NU6140 also effectively inhibits Aurora A and Aurora B (IC50s: 67 and 35 nM, respectively). It also enhances the apoptotic effect and has anti-cancer activity.
BP13393	Fosifloxuridine nafalbenamide
BP13393	NUC-3373 (Fosifloxuridine nafalbenamide), a pyrimidine nucleotide analogue, is a Thymidylate synthase inhibitor.NUC-3373 has anticancer activity. NUC-3373 is a ProTide transformation of 5-FU that generates much higher concentrations of FUDR-MP in patients' cells.
BP13394	NVP-LCQ195
BP13394	NVP-LCQ195 (AT9311) is a potent inhibitor of CDK1, CDK2, CDK3 and CDK5 (IC50: 1-42 nM).
BP13395	NY2267
BP13395	NY2267 is a disruptor of Myc-Max interaction, with an IC50 of 36.5 μM.
BP13396	Olomoucine
BP13396	Olomoucine is an ATP competitive inhibitor of Cdk2/cyclin A, Cdc2/CyclinB, CDK2/CyclinE, CDK5/p35, and ERK1/p44 MAP kinase with IC50s of 7, 7, 7, 3 and 25 µM, respectively. Olomoucine regulates cell cycle and exhibits anti-melanin tumor activities.
BP13397	ON-013100
BP13397	ON-013100 is an antineoplastic drug. ON-013100 also acts as a mitotic inhibitor that could inhibit Cyclin D1 expression.
BP13398	ON-01910
BP13398	ON-01910 is a non-ATP-competitive PLK1 inhibitor(IC50 of 9 nM, in a cell-free assay). It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Rigosertib inhibits PI3K/Akt pathway and activates oxidative stress signals. Rigosertib induces apoptosis in various cancer cells.It is a synthetic benzyl styryl sulfone analogue with potential antineoplastic activity.
BP13399	Orotic acid
BP13399	Orotic acid is an intermediate product in pyrimidine metabolism.
BP13400	Orotic acid zinc
BP13400	Orotic acid zinc salt dihydrate is an intermediate product in pyrimidine synthesis.
BP13401	Osalmid
BP13401	Osalmid is a choleretic drug, inhibits ribonucleotide reductase activity by targeting ribonucleotide reductase small subunit M2 (RRM2).
BP13402	Oxolinic acid
BP13402	Oxolinic acid is a synthetic antimicrobial related to NALIDIXIC ACID and used in URINARY TRACT INFECTIONS.
BP13403	P005091
BP13403	P005091 is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with EC50 of 4.2 μM.
BP13404	P18IN011
BP13404	P18IN011 is a novel inhibitor of p18(INK4C).
BP13405	P 22077
BP13405	P22077 is an inhibitor of ubiquitin-specific protease USP7 with EC50 of 8.6 μM. It also inhibits the closely related USP47.
BP13406	Palbociclib monohydrochloride
BP13406	Palbociclib (PD-0332991) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.
BP13407	Palbociclib Isethionate
BP13407	Palbociclib (PD-0332991) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.
BP13408	Palbociclib-d8
BP13408	Palbociclib D8 is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active inhibitor of CDK4 and CDK6 (IC50s of 11 and 16 nM, respectively).